不同剂量米非司酮治疗子宫壁间肌瘤的临床疗效及安全性研究  

Clinical Efficacy and Safety of Different Doses of Mifepristone in the Treatment of Uterine Wall Myoma

作　　者：王艳丹 WANG Yan-dan(Department of Gynecology, Yutai County People's Hospital, Jining, Shandong Province, 272300 China)

机构地区：[1]鱼台县人民医院妇科

出　　处：《系统医学》2019年第13期129-131,共3页Systems Medicine

摘　　要：目的探究不同剂量米非司酮用于子宫壁间肌瘤治疗中的临床疗效及安全性.方法选取2016年6月—2017年12月收治的108例子宫壁间肌瘤患者临床资料进行分析,将大剂量米非司酮治疗者设作对照组(54例),小剂量米非司酮治疗者设作研究组(54例),比较两组肌瘤与子宫大小、激素水平及不良反应.结果对照组治疗后肌瘤体积(29.35±7.78)cm3、子宫体积(128.36±30.57)cm^3均缩小(t=11.0968、2.8965,P<0.05),且研究组治疗后肌瘤与子宫体积亦缩小(t=11.8030、3.9923,P<0.05),两组治疗后对比差异无统计学意义(P>0.05);研究组治疗后LH(10.87±3.01)IU/mL、FSH(11.25±3.16)μg/L、E2(157.93±8.76)pmol/L等激素水平与对照组治疗后各激素指标水平均较治疗前下降(P<0.05),但二者治疗后激素水平差异无统计学意义(P>0.05);研究组不良反应总发生率11.11%较对照组显著低(x^2=8.7961,P<0.05).结论宫壁间肌瘤经大剂量或小剂量米非司酮治疗后均可取得良好治疗效果,但小剂量用药不良反应更少,具一定临床应用与研究价值.Objective To investigate the clinical efficacy and safety of different doses of mifepristone in the treatment of uterine wall myoma. Methods The clinical data of 108 patients with uterine fibroma who were admitted to our hospital from June 2016 to December 2017 were analyzed. The cases with high-dose mifepristone were taken as the control group (54 cases), and the cases with low-dose mifepristone were taken as the study group (54 cases). The size of the fibroids and uterus, hormone levels, and adverse effects were compared between the two groups. Results After treatment, the fibroid volume (29.35±7.78)cm^3 and uterine volume (128.36±30.57)cm3 were reduced in the control group (t=11.096 8;2.896 5,P<0.05). And the fibroid volume and uterus volume were also reduced after treatment in the study group (t=11.803 0;3.992 3,P<0.05), and there was no statistically significant difference in height after treatment between the two groups (P>0.05). LH (10.87±3.01) IU/mL, FSH(11.25±3.16)μg/L, E2(157.93±8.76)pmol/L after treatment in the study group were decreased after treatment. There was no statistically significant difference in hormone levels after treatment between the two groups (P>0.05). The total incidence of adverse reactions in the study group was 11.11%, which was significantly lower than that in the control group (χ^2=8.796 1,P<0.05). Conclusion Uterine wall fibroids can achieve good therapeutic effects after high-dose or low-dose mifepristone treatment, but there are fewer adverse reactions in low-dose medications, which have certain clinical application and research value.

关 键 词：米非司酮 不同剂量 子宫壁间肌瘤 

分 类 号：R737.33[医药卫生—肿瘤]